Renalytix plc

Climate Impact & Sustainability Data (2023, 2024)

Monitors staff attrition rates and aims to keep them low.
Aims to structure staff compensation levels at competitive rates to attract and retain high-calibre personnel.
Applications for employment by disabled persons are always fully considered.
Encourages employees to take part in charitable activities.

Adopted the corporate governance principles of the 2018 Quoted Companies Governance Code.

Recurring losses and negative cash flows from operations since inception.
Substantial doubt exists about the Group and Company’s ability to continue as a going concern.
Substantial additional capital will be necessary to fund operations, expand commercial activities, and develop other potential diagnostic-related products.
Dependency upon strategic collaboration with third-party partners.
Regulatory risk.
Reimbursement levels.
Dependence on key employees.
Obsolescence of Group’s products.
Increasingly stringent privacy and data security legislation.
Competition.
Research and development risk.
Cyber security risk.
Intellectual property risk.

Seeking additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances, and licensing arrangements.
Implementation of various additional operating cost reduction options.
Achievement of a certain volume of assumed revenue.
Seeking advice from regulatory advisors, consultations with regulatory approval bodies, and working with experienced partners.
Constant dialogue and educating third-party payers on the Group’s products and developing new technologies to seek additional reimbursements.
Competitive remuneration structure, including share-based incentives, and key-man insurance.
Developing and adapting to technological changes and industry trends.
Robust security measures, staff training, and back-up systems.
Developing products where legal advice indicates patent protection would be available, seeking patent protection for the Group’s products, maintaining confidentiality agreements, and monitoring technological developments.
Careful management of projects.

Frameworks Used: Quoted Companies Governance Code (2018)

Closely monitors staff attrition rates which it seeks to keep at low levels and aims to structure staff compensation levels at competitive rates in order to attract and retain high calibre personnel.
Applications for employment by disabled persons are always fully considered, bearing in mind the specific aptitudes of the applicant involved. It is the policy of the Group that the training, career development and promotion of disabled persons, as far as possible, be identical to that of other employees.
The Group encourages employees to take part in charitable activities which are related to our business areas or customers. It contributes as far as is practicable to the local communities in which it operates and takes a responsible and positive approach to employment practices.

Achieved FDA De Novo marketing authorization for kidneyintelX.dkd to assess risk of progressive kidney function decline in adults with diabetes and early-stage kidney disease
Secured additional key insurance coverage contracts for KidneyIntelX
Inclusion of KidneyIntelX in draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease (KDIGO 2023 Guideline)
Continuing to maintain contracted pricing at or over the Medicare Clinical Laboratory Fee Schedule (CLFS) of $950 per reportable test result
Continued receiving Medicare payments for KidneyIntelX
Executed over 40 commercial payor contracts and enrolled as a provider in 35 state Medicaid programs to date
Milestone achievement converting payment to full, long-term commercial insurance billing model at Mount Sinai Health System
Appointed senior diagnostics executive Howard Doran to lead global commercial sales beginning with direct to physician salesforce in New York, Illinois, North Carolina, Florida and Texas
Full Epic electronic health record system integration with Atrium / Wake Forest proceeding with launch expected before end of calendar 2023
Core participant in consortium granted $10 million by Horizon Europe Grant to advance personalized medicine in treating chronic kidney disease

The Group is dependent upon its strategic collaboration with third party partners
Regulatory risk
Reimbursement levels
Key employees
Obsolescence of Group’s products
Increasingly stringent privacy and data security legislation
Competition
Research and development risk
Financial reporting and disclosure
Cyber security risk
Intellectual property risk

Seeks advice from regulatory advisers, consultations with regulatory approval bodies and by working with experienced partners.
Constant dialogue and educating the third-party payers on the Group’s products and also developing new technologies in order to seek additional reimbursements.
Competitive remuneration structure, which includes share-based incentives. Key-man insurance on James McCullough.
Careful management of projects.
Robust security measures, staff training, and back-up systems.
Developing products where legal advice indicates patent protection would be available, seeking patent protection for the Group’s products, maintaining confidentiality agreements regarding Group know-how and technology and monitoring technological developments and the registration of patents by other parties.